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s aIntroduction: The purpose of this study is to better understand the quit experience and concerns of
smokers with psychiatric illness (i.e., major depressive, anxiety, psychotic and bipolar disorders) in
comparison with those without psychiatric illness.
Methods: Smokers (N¼732) with (n¼430, 59%) and without psychiatric illness, recruited between
June 2010 and March 2013 to participate in the FLEX (Flexible and Extended Dosing of Nicotine
Replacement Therapy [NRT] and Varenicline in Comparison to Fixed-Dose NRT for Smoking
Cessation) smoking-cessation trial, completed questionnaires assessing previously used cessation
aids and reasons for relapse, and motivation and concerns about their upcoming quit attempt. These
supplementary data analyses were conducted in May 2015.
Results: The most commonly used cessation methods during previous attempts were nicotine
replacement therapy (66.4%), cold turkey (59.7%), and bupropion (34.7%); no group differences
were identiﬁed. Stress was the most common precipitator of relapse during previous attempts in all
groups (43.6%), particularly among participants with depression and anxiety. Health was the most
common motivation for the upcoming quit attempt (91%), followed by family/social pressures
(28.1%) and cost (27.9%, particularly by smokers with psychotic disorders). Common pre-cessation
concerns for the complete sample included: cravings (27.6%), stress (26.7%), and fear of failure
(26%); participants with psychotic and anxiety disorders were most concerned about cravings,
whereas the latter two concerns were more prominent for individuals with anxiety.
Conclusions: Findings reveal differences in the quit histories and concerns of smokers with or
without psychiatric illness. Smokers with psychiatric illness are particularly vulnerable to relapse at
times of stress and negative affect; interventions that emphasize alternative coping strategies and
facilitate mood management are required.
(Am J Prev Med 2016;50(6):709–718) & 2016 American Journal of Preventive Medicine. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionTobacco addiction is the leading cause of prevent-able death worldwide.1 Despite the decline in therates of smoking in Canada and the U.S. in the
past three decades, almost one in ﬁve citizens continue to
smoke.2,3 The prevalence of smoking is disproportion-
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rticle under the CC BY-NC-ND license (http://creativecoA national U.S. survey identiﬁed that 41% of people with
a mental illness are smokers,4 and 80% of individuals
with schizophrenia, 69% of those with bipolar, 46% of
those with generalized anxiety disorder, and 37% of those
with major depression currently smoke.5,6 Those experi-
encing psychiatric illness are heavy smokers; 44% of
current U.S. cigarette consumption is attributed to those
with psychiatric diagnoses.4 Smoking is a major contri-
buting factor for the high rates of chronic disease (e.g.,
coronary artery disease) and reduced life expectancy of
patients with psychiatric illness—25 years fewer than the
general population.7-9
Nicotine dependence has been described as a chronic,
relapsing condition; only 3%5% of smokers are success-
ful during any one given unassisted quit attempt.10 The
factors contributing to relapse are numerous,11 includingier Inc. This is an
mmons.org/licenses/by-nc-nd/4.0/).
Am J Prev Med 2016;50(6):709–718 709
Tulloch et al / Am J Prev Med 2016;50(6):709–718710an intention that a lapse be temporary (i.e., smoke one
cigarette and thereafter remain abstinent),12,13 impulsive-
ness, high nicotine dependence, a desire to reduce craving
and withdrawal symptoms,14,15 low self-efﬁcacy,16 expect-
ation of reduced anxiety,17 and having a partner that
smokes.18 The two most-often cited potent predictors of
relapse, however, are stress and negative affect.13,19,20
Intuition would dictate that stress and negative affect
are especially problematic among those with mental
illness, but surprisingly little is known about reasons
for relapse among psychiatric patients. Only two studies
have explored the relapse experiences of mental health
patients.21,22 Results demonstrated that the pleasure of a
cigarette, a temporary planned lapse, other smokers,
stress, and cravings typically led to the resumption of
smoking. More research involving smokers with mental
illness is required to better understand the factors related
to relapse and to improve clinical interventions for such
smokers.
Furthermore, much is now known about the reasons
for quitting smoking in the general population23; this,
however, is not the case for those with psychiatric
disorders. A recent systematic review investigated rea-
sons for quitting among people with mental illness.24
Nicotine addiction and cravings, stress and negative
affect reduction, the desire for relaxation and pleasure,
sensorimotor manipulation, and stimulation were iden-
tiﬁed as reasons for smoking. Others have documented
that anhedonia among patients with a history of depres-
sion25 and social facilitation among patients with schiz-
ophrenia promote continued tobacco use.26,27 Like their
healthy counterparts, smokers with severe mental illness
rate health, well-being, and ﬁnances as perceived beneﬁts
of quitting smoking.28,29 Possibly because of the known
neurobiological interactions that provide a degree of
symptom relief to patients with psychotic disorders (e.g.,
improved sensory gating deﬁcits and alertness), most
studies have investigated smoking experiences in such
patients. In fact, ﬁve of the six studies included in the
review by Thornton et al.24 included only psychotic
patients; this gap leaves unanswered questions about
the quit experiences among those with other psychiatric
conditions.
Finally, little is known about the pharmaceutical and
behavioral cessation methods selected by smokers with
mental health issues. Recent population-level and clinical
database studies show that nicotine replacement therapy
(NRT) is the method of choice for smokers in the general
population, followed by the use of varenicline and
bupropion.30,31 One small study (N=78) examined the
quit methods used by former smokers with mental illness
and showed that social support and various smoking-
cessation medication (31% used NRT, 6% varenicline, 4%bupropion) enabled smokers to quit.28 To date, no study
has compared cessation strategies between psychiatric
and non-psychiatric patients.
A fundamental understanding of the unique quitting
experience of smokers with psychiatric illness could
shape smoking-cessation interventions and relapse pre-
vention programs so as to render them more effective.
The purpose of the present study was to better under-
stand the quit experiences of smokers with psychiatric
illnesses in comparison with those without psychiatric
comorbidities. Previously used cessation aids, reasons for
relapse during past quit attempts, and the motivating
factors and concerns that surround an upcoming cessa-
tion attempt were examined.
Methods
Participants and Procedures
Treatment-seeking smokers from the general population were
recruited between June 2010 and March 2013 by advertising, from
physicians, by word of mouth, and through the quit smoking
program at the University of Ottawa Heart Institute to participate
in the FLEX (Flexible and Extended Dosing of NRT and
Varenicline in Comparison to Fixed-Dose NRT for Smoking
Cessation) trial.32 Inclusion criteria were: ageZ18 years, smoking
ten or more cigarettes per day over the past 6 months, willingness
to make a quit attempt within 24 weeks, and the ability to
provide informed consent. Exclusion criteria included: current or
past-month (>72 consecutive hours) use of the smoking-cessation
pharmacologic interventions; having contraindications to the use
of varenicline or NRT products; being pregnant, breastfeeding, or
intending to become pregnant within the next year; current or
previous (past 3 months) substance abuse; inability to provide
informed consent owing to unstable psychiatric symptoms (i.e.,
active, untreated psychosis or suicidality); or an inability to read/
write in English or French. Only one person per household could
participate in the trial. The study received approval from the
Ottawa Health Sciences Network Research Ethics Board.
The present study includes supplementary analyses of data
obtained during the baseline assessment of the FLEX trial. At
baseline, participants engaged in a clinical psychiatric interview
and completed questionnaires regarding demographic informa-
tion, previous quit experiences, and motivation and concerns
about an upcoming attempt (next 30 days).Measures
Participants reported their age, gender, education, and marital and
employment status. Smoking-related variables included the age at
which participants smoked their ﬁrst cigarette, years smoked, and
number of quit attempts in the previous year. From a list of
potential responses, participants reported which cessation aids
they had used in the past for at least 24 hours for smoking
cessation (e.g., cold turkey, NRT, hypnosis), reason(s) for relapsing
to smoking (e.g., negative affect, other smokers, cravings), and
motives (e.g., health, cost of cigarettes) and concerns (e.g., fear of
failure, weight gain, stress) about the upcoming quit attempt.www.ajpmonline.org
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history using the Mini International Psychiatric Interview
6.0.0,33,34 a structured diagnostic interview used to assess DSM-
IV and ICD-10 psychiatric disorders. Participants who did not
meet any psychiatric diagnostic criteria in their lifetime were
classiﬁed as “none,” whereas individuals who met lifetime (current
or past) criteria were classiﬁed into one of four primary diagnoses:
major depressive disorder, bipolar disorder, anxiety disorders (i.e.,
phobias, generalized anxiety disorder, post-traumatic stress dis-
order, panic disorder), and psychotic disorders. For individuals
with comorbid diagnoses, the primary diagnosis was reviewed and
determined by the study psychologist (HT) and psychiatrist (CE)
using the following classiﬁcation criteria:1.Juncurrent superseded past diagnoses (e.g., current generalized
anxiety and past major depression would be classiﬁed as an
anxiety disorders);2. more severe superseded less severe diagnosis (e.g., comorbid
psychotic and major depression would be classiﬁed as a
psychotic disorder); and3. if equivalent in severity and duration (current/past), the
disorder that warranted the most treatment attention and
had the greatest impact on the participant’s functioning was
classiﬁed as the primary diagnosis.
Statistical Analysis
Statistical analyses were conducted in May 2015. Initial compar-
isons between psychiatric groups were made for demographic and
smoking history variables using ANOVA (with Tukey’s honest
signiﬁcant difference post-hoc test for group differences) for
continuous measures and chi-square tests for categorical variables.
Next, variables related to previous quit attempts and the upcoming
quit attempt were compared for any psychiatric diagnosis versus
no diagnosis using chi-square tests. In addition, the ﬁve psychiatric
diagnosis groups (i.e., none, depression, anxiety, bipolar, and
psychotic) were compared using chi-square tests; adjusted resid-
uals (z-scores) were calculated for multiple comparisons (Bonfer-
roni method, α=0.05) to determine which cells were signiﬁcantly
different. Previous quit attempt and upcoming quit attempt
variables that were signiﬁcantly different between the psychiatric
diagnosis groups were then re-analyzed using a logistic regression
(ref, no diagnosis), controlling for those demographic and smok-
ing history variables that were signiﬁcantly different in the initial
analyses (AORs with 95% CIs). All analyses were conducted using
SPSS, version 21, using an α of 0.05 to determine statistical
signiﬁcance.
Results
A total of 737 individuals participated; of these, 59% met
diagnostic criteria for a psychiatric disorder. Owing to a
very small sample size that restricted the power of
comparisons to the other groups, participants who met
diagnostic criteria for substance abuse in the previous 12
months (but not the last 3 months) alone were excluded
from the analyses (n=5), leaving a ﬁnal sample size of
732 smokers. A small number of participants (n=42)e 2016reported no previous quit attempts; these individuals
were excluded from the analyses regarding previous quit
attempts. In general, the sample comprised chronic
smokers, smoking >23 cigarettes per day and having
smoked for >31 years on average.
Table 1 displays the participants’ demographic and
smoking history by psychiatric diagnosis. The sample
had a mean age of 48.6 (SD¼10.83) years; individuals
with anxiety disorders were slightly younger. The sample
was fairly equally distributed across the sexes; individuals
with a diagnosis of either depression, bipolar disorder, or
anxiety were more likely to be female, whereas those with
no diagnosis or psychotic disorders were more likely to
be male. Approximately half of the sample (46%) was
married or living with a partner. Individuals with no
lifetime diagnosis were more likely to be married
compared with those with bipolar or psychotic disorders;
those diagnosed with depression tended to be separated,
divorced, or widowed compared with those with no
diagnosis; and those with a psychotic disorder were more
likely to be single as compared with those with depres-
sion, anxiety, or no diagnosis. Participants had com-
pleted, on average, 14 years of formal education;
participants with depression had less education than
those in the nonpsychiatric group. The majority of the
sample (61%) was employed full-time or part-time; those
with any psychiatric diagnosis were more likely to be
receiving disability beneﬁts compared with those with no
diagnosis. Participants with depression had smoked
longer than those with anxiety (p¼0.029). Participants
with bipolar and psychotic disorders smoked signiﬁ-
cantly more cigarettes than did those with no diagnosis
(p¼0.025 and po0.001, respectively).
Table 2 displays the quit methods previously employed
by participants. Transdermal NRT was the most com-
monmethod used by all groups (69.5%), followed by cold
turkey (62.6%), bupropion (36.1%), and NRT gum
(35.7%). Group differences were observed in the use of
bupropion (p¼0.005), varenicline (p¼0.017), and hyp-
nosis (p¼0.048) in the chi-square analyses, but were no
longer signiﬁcant after adjustment for confounding
variables (all p-values >0.10). Few participants reported
individual- or group-based smoking-cessation counsel-
ing (6%); no differences were found between groups in
this regard.
Reasons for a relapse to smoking are presented in
Table 2. Stress was the most common response in all
groups (endorsed by 45.6%). Stress and negative affect
were signiﬁcantly different between those with and
without any lifetime diagnosis (p-values r0.01). Com-
pared with those with no diagnosis, stress was more likely
to be endorsed by those with depression (AOR¼1.55,
95% CI¼1.08, 2.23) and anxiety (AOR¼1.83, 95%
Table 1. Demographics and Smoking History Variables by Psychiatric Diagnosis
Variables
Overall
(N¼732)
None
(n¼302)
Any psychiatric
diagnosisa
(n¼430)
Depression
(n¼281)
Anxiety
(n¼93)
Bipolar disorders
(n¼38)
Psychotic
disorders
(n¼18) p-value
Age (years), M (SD) 48.61 (10.83) 48.54 (11.01) 48.63 (10.67) 49.94 (10.59) 45.48 (10.99) 47.16 (9.25) 48.61 (10.83) 0.013
Male, n (%) 390 (53.3) 188 (62.3) 203 (47.6) 132 (47.0) 41 (44.1) 14 (36.8) 15 (83.3) o0.001
Female, n (%) 342 (46.7) 114 (37.7) 226 (52.4) 149 (53.0) 52 (55.9) 24 (63.2) 3 (16.7)
Marital status, n (%)
Single 160 (22.0) 52 (17.3) 104 (25.2) 57 (20.4) 25 (20.9) 14 (36.8) 12 (70.6) o0.001
Common law/
married
337 (46.3) 172 (57.3) 168 (38.8) 110 (39.3) 39 (41.9) 14 (36.8) 2 (11.8)
Separated/divorced
/widowed
231 (31.7) 76 (25.3) 156 (36.0) 113 (40.4) 29 (31.2) 10 (26.3) 3 (17.7)
Education (years),
M (SD)
14.13 (2.95) 14.60 (2.81) 13.79 (3.01)** 13.78 (3.00) 13.88 (3.22) 13.55 (2.67) 14.13 (2.95) 0.008
Employment, n (%)
Working full- or
part-time
445 (61.1) 226 (75.6) 223 (51.4) 149 (53.2) 51 (54.8) 15 (39.5) 4 (22.2) o0.001
Retired 92 (12.6) 41 (13.7) 51 (11.8) 38 (13.6) 6 (6.5) 5 (13.2) 2 (11.1)
Unemployed/HM 66 (9.1) 19 (6.4) 47 (10.8) 33 (11.8) 10 (10.8) 3 (7.9) 1 (5.6)
Disability leave 125 (17.2) 13 (4.3) 113 (26.0) 60 (21.4) 26 (28.0) 15 (39.5) 11 (61.1)
Smoking, M (SD)
Age (years) at ﬁrst
cigarette
14.48 (4.03) 14.78 (4.3) 14.26 (3.83) 14.30 (4.1) 14.11 (3.2) 13.68 (3.0) 15.72 (3.5) 0.187
Years smoked 31.04 (11.7) 30.84 (11.8) 31.20 (11.59) 32.43 (11.6) 28.35 (11.5) 30.74 (10.7) 27.50 (11.41) 0.031
Cigarettes/day 23.24 (10.8) 21.96 (9.6) 24.15 (11.38)* 23.41 (10.1) 23.34 (11.9) 27.36 (14.5) 33.18 (16.7) o0.001
No. of quit attempts 4.66 (5.83) 4.52 (6.1) 4.74 (6.20) 4.95 (6.0) 4.64 (5.1) 3.64 (2.4) 4.75 (5.9) 0.752
Note: Boldface indicates statistical signiﬁcance (*po0.01; **po0.001). Statistical analyses conducted: ANOVA for continuous variables (age, education, age of ﬁrst cigarette, years smoked, cigarettes/
day, quit attempt); χ2 for categorical variables (gender, marital status, employment status).
aCompared with None (i.e., no diagnosis).
HM, homemaker.
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Table 2. Quit Methods Used and Reasons Identiﬁed for Relapsing to Smoking During a Previous Quit Attempt by Psychiatric Diagnosis
Variables
Total sample,
n (%)
(N¼689)
None,
n (%)
(n¼280)
Any psychiatric
diagnosis,a
n (%) (n¼409)
Depression,
n (%)
(n¼268)
Anxiety
disorder, n (%)
(n¼89)
Bipolar
disorder, n (%)
(n¼34)
Psychotic
disorder, n (%)
(n¼18)
χ2 p-
valueb
LR
adjusted
p-valuec
Previous quit methods
Patch 479 (69.5) 193 (69.6) 286 (69.1) 184 (68.7) 59 (66.3) 25 (73.5) 13 (72.2) 0.904
Cold turkey 431 (62.6) 180 (64.3) 253 (58.7) 166 (61.9) 56 (62.9) 22 (64.7) 7 (38.9) 0.311
Bupropion 249 (36.1) 122 (43.6) 130 (30.0)*** 88 (32.8) 26 (29.2) 11 (32.4) 2 (11.1) 0.005 0.245
Gum 246 (35.7) 92 (32.9) 156 (37.7) 103 (38.4) 29 (32.6) 12 (35.3) 10 (55.6) 0.255
Varenicline 132 (19.2) 54 (19.3) 79 (19.1) 64 (23.9) 10 (11.2) 2 (5.9) 2 (11.1) 0.017 0.190
Hypnosis 124 (18.0) 46 (17.1) 78 (18.8) 60 (22.4) 13 (14.6) 2 (5.9) 1 (5.6) 0.048 0.172
Inhaler 98 (14.2) 35 (12.9) 63 (15.2) 34 (12.7) 18 (20.2) 8 (23.5) 2 (11.1) 0.190
Acupuncture 66 (9.6) 28 (10.0) 38 (9.2) 26 (9.7) 10 (11.2) 2 (5.9) 0 (0) 0.594
Lozenge 63 (9.1) 23 (8.2) 40 (9.7) 28 (10.4) 10 (11.2) 0 (0) 2 (11.1) 0.307
Laser 47 (6.8) 23 (8.52) 25 (6.0) 19 (7.1) 4 (4.5) 1 (2.9) 0 (0) 0.439
Reasons for relapsing
Stress 314 (45.6) 105 (38.2)d 209 (50.5)** 134 (50.0)e 49 (55.1)e 15 (44.1)d,e 7 (38.9)d,e 0.041 0.038
Other smokers 256 (37.2) 100 (36.4) 156 (37.7) 103 (38.4) 34 (38.2) 11 (32.4) 5 (27.8) 0.893
Lack willpower 255 (37.0) 114 (41.5)d 141 (34.1)* 81 (30.2)e 31 (34.8)d,e 16 (47.1)d,e 9 (50.0)d,e 0.032 0.109
Cravings 213 (30.9) 82 (29.8) 131 (31.6) 78 (29.1) 32 (36.0) 13 (38.2) 5 (27.8) 0.759
Negative affect 185 (26.9) 44 (15.7)d 143 (34.5)*** 86 (32.1)e 38 (42.7)e 12 (35.3)e 5 (27.8)d,e o0.001 o0.001
Social outings 172 (25.0) 74 (26.4) 100 (24.2) 65 (24.3) 23 (25.8) 7 (20.6) 3 (16.7) 0.696
Drink alcohol 149 (21.6) 68 (24.3) 85 (20.5) 53 (19.8) 16 (18.0) 6 (17.6) 6 (33.3) 0.223
After eating 133 (19.3) 52 (19.6) 81 (19.6) 46 (17.2) 24 (27.0) 6 (17.6) 2 (11.1) 0.736
Boredom 126 (18.3) 47 (17.9) 78 (18.8) 45 (16.8) 15 (16.9) 12 (35.3) 4 (22.2) 0.203
Drink caffeine 111 (16.1) 37 (13.5) 74 (17.9) 39 (14.6) 21 (23.6) 8 (23.5) 4 (22.2) 0.149
Stopped cessation
medications
95 (13.7) 38 (13.5) 57 (13.8) 41 (15.3) 12 (13.5) 3 (8.8) 0 (0) 0.608d
Note: Boldface indicates statistical signiﬁcance (*po0.05; **po0.01; ***po0.001).
aAny psychiatric diagnosis analyses were analyzed in 22 contingency tables (no lifetime versus any lifetime diagnosis) and χ2 unadjusted p-values are presented.
bχ2 unadjusted p-value reported for 52 tables (none, depression, bipolar, anxiety, psychotic diagnoses).
cLR adjusted p-value¼overall logistic regression adjusted p-value.
d,eColumn proportions (for each row) that differ signiﬁcantly from each other, corrected for multiple comparisons using Bonferroni adjustment (po0.05) for the 5 psychiatric groups.
LR, logistic regression.
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endorsed by those with depression (AOR¼2.41, 95%
CI¼1.56, 3.72), bipolar disorder (AOR¼2.79, 95%
CI¼1.25, 6.21), and anxiety (AOR¼3.60, 95% CI¼2.06,
6.29). Those with no psychiatric diagnosis were more
likely to report lack of willpower as a reason for relapse
compared with individuals with depression (AOR¼0.61,
95% CI¼0.42, 0.88). Being alone, weight gain, seeing
smoking stimuli (e.g., cigarettes), and when relaxing
were endorsed by o10% of the sample as contri-
buting to relapse; no differences between groups were
revealed.
Participants endorsed various reasons for quitting
(Table 3). Overall, health was the most common response
(91%), followed by family/social pressures (28.1%) and
cost of cigarettes (27.9%). Those with a psychotic
disorder were more likely to report the cost of cigarettes
as a reason to quit when compared with those with no
diagnosis (AOR¼3.21, 95% CI¼1.11, 9.30). Those with
no diagnosis were more likely to report others’ health
(e.g., for a child or partner) as a reason to quit smoking
compared with individuals with depression (AOR¼0.56,
95% CI¼0.35, 0.91).
Table 3 also displays the participants’ concerns about
their upcoming quit attempt. Cravings were the most
common concern for smokers in this study (27.6%),
followed closely by stress (26.7%) and fear of failure
(26%). Compared with those with no diagnosis,
those with anxiety disorders were more likely to
report stress (AOR¼3.27, 95% CI¼1.93, 5.56), fear of
failure (AOR¼2.23, 95% CI¼1.30, 3.83), and mood
(AOR¼2.31, 95% CI¼1.29, 4.13) as concerns for quit-
ting. Smokers with psychotic disorders were also more
likely to endorse craving as a concern (AOR¼4.16, 95%
CI¼1.44, 12.06), and boredom was a signiﬁcant concern
for those with anxiety (AOR¼2.75, 95% CI¼1.29, 5.90)
and psychotic disorders (AOR¼8.03, 95% CI¼2.25,
28.69) as compared with those with no diagnosis. A
small percentage of participants (o2%) were concerned
about missing the enjoyment of smoking, managing
smoking-cessation medications, and when drinking or
eating.
Discussion
Promoting smoking cessation is a global public health
priority. Smokers with psychiatric diagnoses represent a
growing proportion of the smoking population, suffer
from smoking-related diseases at a disproportionate rate,
and require improved intervention efforts.35 An under-
standing of their cessation concerns and experiences is
particularly important if clinicians are to be more
effective in stimulating and supporting their cessationattempts. The present study is one of few to have
investigated the quit experience and concerns of smokers
with and without a psychiatric diagnosis,36 mental health
patients’ reasons to consider quitting and for relapse, and
it is the ﬁrst study to include a sample presenting with
various psychiatric diagnoses. The ﬁndings indicate that
important differences exist in the quit experiences and
perceptions between these groups of smokers.
The number one quit method for all smokers was
NRT. With the exception of slightly higher rates of
bupropion use, the results presented herein are similar to
general population data from the United Kingdom
reporting that 68%78% of smokers used NRT, 5%8%
tried bupropion, and 14%26% used varenicline.30,31
On one hand, these results are encouraging—all groups
have used a variety of cessation products that have proven
effective for smoking cessation.37 On the other hand, more
than half of the sample tried to quit “cold turkey.”
U.S. national data also show limited use of cessation
treatments.38 To curb craving and withdrawal symptoms,
clinicians should be encouraged to prescribe pharmaco-
therapy for smokers wanting to quit. Population-level
studies, clinical databases, and recent RCTs have provided
assurance that these medications do not lead to any
worsening of psychiatric symptoms.30,31,39
Data from the present study suggest that smokers,
especially those with a lifetime diagnosis of major
depressive and anxiety disorders, report stress and
negative affect as common precursors to relapse. These
results are consistent with previous publications with
general13,19,20 and mental health populations.21,22
Research shows that all smokers, but especially those
with psychiatric disorders, retain the belief that smoking
produces positive emotional states (e.g., relaxation,
pleasure)40,41; it is not surprising that negative affect
often precedes a lapse in smoking cessation. It has been
suggested that the perceived beneﬁts of smoking when
stressed are a misattribution of nicotine withdrawal
relief.42 Future interventions would do well to emphasize
the importance of identifying negative mood as a time of
vulnerability and equip smokers with alternative, healthy
coping mechanisms. Clinicians need to debunk the
misinformation and misperceptions of the expectancies
of smoking. For example, emerging evidence demon-
strates that anxiety and depression symptoms actually
decrease, and psychotic symptoms remain stable with
abstinence.43-45 An educational component that high-
lights the psychological beneﬁts of abstinence and
challenges the positive expectations of smoking might
add value to cessation interventions.
Results showed that smokers with psychiatric diag-
noses attempted to quit at similar rates as those without
psychiatric comorbidity. The most common reasons towww.ajpmonline.org
Table 3. Most Endorsed Reasons for Quitting and Concerns About Quitting for Upcoming Quit Attempt by Psychiatric Diagnosis
Variables
Total sample,
n (%)
(n¼732)
None,
n (%)
(n¼302)
Any psychiatric
diagnosis,a n (%)
(n¼430)
Depression,
n (%)
(n¼281)
Anxiety
disorder,
n (%) (n¼93)
Bipolar
disorder,
n (%) (n¼38)
Psychotic
disorder, n (%)
(n¼18)
χ2
p-valueb
LR
adjusted
p-valuec
Reasons for quitting
Health 662 (90.9) 270 (89.7) 396 (91.7) 252 (90.3) 89 (96.7) 33 (86.8) 18 (100) 0.135
Family/social
pressure
203 (28.1) 80 (27.0) 125 (28.9) 80 (28.7) 28 (30.4) 11 (28.9) 4 (22.2) 0.952
Cost 204 (28.0) 72 (23.9)d 134 (31.0) 81 (29.0)d 29 (31.5)d,e 11 (28.9)d,e 11 (61.1)e 0.011 0.024
Others’ health 120 (16.5) 61 (20.3)d 63 (14.6) 35 (12.5)d 19 (20.7)d 5 (13.2)d 0 (0)e 0.023d 0.016
Doctor’s advice 103 (14.1) 41 (13.6) 62 (14.4) 35 (12.5) 16 (17.4) 7 (18.4) 4 (22.2) 0.569
Other 68 (9.3) 33 (11.0) 35 (8.1) 27 (9.7) 5 (5.4) 2 (5.3) 1 (5.6) 0.452
Athletic activities 51 (7.0) 17 (5.6) 34 (7.9) 23 (8.2) 8 (8.7) 1 (2.6) 2 (11.1) 0.475
Stress 37 (5.1) 11 (3.7) 27 (6.2) 14 (5.0) 9 (9.8) 1 (2.6) 2 (11.1) 0.112
Smell or taste 31 (4.2) 13 (4.2) 18 (4.1) 11 (3.9) 3 (3.2) 3 (7.9) 1 (5.6) 0.811f
Concerns about quitting
Cravings 201 (27.6) 75 (24.9) 128 (29.7) 76 (27.2) 29 (31.9) 11 (28.9) 10 (55.6) 0.061
Stress 195 (26.8) 66 (21.9)d 131 (30.4) 75 (26.9)d 41 (45.1)e 7 (18.4)d 6 (33.3)d,e o0.001 0.001
Fear of failure 188 (25.9) 68 (22.6)d 120 (27.8) 74 (26.5)d,e 34 (37.4)e 10 (26.3)d,e 2 (11.1)d,e 0.039 0.038
Weight gain 153 (21.0) 66 (21.9) 88 (20.4) 60 (21.5) 19 (20.9) 5 (13.2) 3 (16.7) 0.771
Mood 136 (18.7) 46 (15.3)d 91 (21.1) 45 (16.1)d 28 (30.8)e 11 (28.9)d,e 6 (33.3)d,e 0.002 0.006
Willpower 122 (16.8) 50 (16.6) 72 (16.7) 45 (16.2) 18 (19.8) 5 (13.2) 4 (22.2) 0.844
Other smokers 116 (16.0) 38 (12.6) 78 (18.1) 52 (18.6) 16 (17.6) 5 (13.2) 5 (27.8) 0.180
Boredom 71 (9.8) 20 (6.6)d 52 (12.1) 29 (10.4)d,e 14 (15.4)d,e 3 (7.9)d 5 (27.8)e 0.009 0.007
Other 58 (8.0) 25 (8.3) 33 (7.7) 20 (7.2) 7 (7.7) 6 (15.8) 0 (0) 0.285
Celebration 57 (7.8) 24 (8.0) 33 (7.7) 20 (7.2) 8 (8.8) 3 (7.9) 2 (11.1) 0.967
Note: Boldface indicates statistical signiﬁcance (po0.05).
aAny psychiatric diagnosis analyses were analyzed in 22 contingency tables (no lifetime versus any lifetime diagnosis) and χ2 unadjusted p-values are presented.
bχ2 unadjusted p-value reported for 52 tables (none, depression, bipolar, anxiety, psychotic diagnoses).
cLR adjusted p-value¼overall logistic regression adjusted p-values.
d,eColumn proportions (for each row) that differ signiﬁcantly (z-test) from each other, corrected for multiple comparisons using Bonferroni adjusted p-values.
fFisher’s exact test p-value (420% of cases with expected count o5).
LR, logistic regression.
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Tulloch et al / Am J Prev Med 2016;50(6):709–718716quit reported by the current sample included health,
social or family pressure, cost of cigarettes, and other’s
health. Participants with psychotic disorders were partic-
ularly motivated by ﬁnancial concerns; this ﬁnding is
expected considering that psychiatric patients tend to be
low-income and in receipt of disability beneﬁts. The
results also corroborate previous ﬁndings that health is
an important motivator to quit smoking among all
smokers.23,28,29,46 However, it is important to note that
psychotic patients in a previous study reported lower
perceived health risks with smoking than did nonpsychi-
atric controls26; interventions are needed to address this
misconception.
Despite their motivation to quit, psychiatric patients,
especially those with anxiety and psychotic disorders,
expressed many concerns in the weeks before a target
quit date. As reported in the general population,47
craving is a key concern for smokers with psychiatric
disorders. Clinicians would do well to offer pharmaco-
therapy to all smokers37 and to draw attention to the
efﬁcacy of these products in managing craving and the
symptoms of withdrawal and enhancing the likelihood of
successful cessation. Participants, particularly those with
anxiety disorders, were worried about coping with stress,
fear of failure, and mood changes when attempting to
quit. Other researchers have also reported a fear of
deteriorating mental health (e.g., worry about increasing
anxiety levels) and loss of a coping strategy as concerns
about quitting within this population.48 Those with
psychiatric conditions contemplating and attempting
cessation should be provided with cessation aids, sup-
port, and more-clearly articulated strategies for stress
management. Mental health patients themselves have
expressed interest in additional professional support and
better mood management during a quit attempt.49 More
intensive and integrated smoking-cessation interventions
for psychiatric patients may be required.35,50Limitations
Despite the strengths of the present study, it is not
without limitations. First, the data are cross-sectional,
prohibiting causal inferences. Second, the quit methods
and relapse data are retrospective and may be inﬂuenced
by recall or subjective biases. There are secular factors,
which may have inﬂuenced the use of certain cessation
pharmacotherapies in the past (e.g., cost and availability);
evolving evidence of the safety and suitability of certain
pharmacotherapies may also have been reﬂected in the
reported use of such treatments in the past. Third,
relative to the other groups, the sample of participants
with bipolar and psychotic disorders was small and may
have limited the understanding of factors relevant tocessation attempts and success within this important
patient population. Finally, given that the participants
were treatment-seeking smokers with previous quit
experience, the generalizability of the results to a broader
population of smokers with comorbid conditions is
unknown.
Conclusions
In summary, differences in the quit histories and con-
cerns of smokers with or without psychiatric illness are
evident. Smokers with psychiatric illness are particularly
vulnerable to relapse at times of stress and negative affect;
interventions that facilitate mood management are
required.
This project is supported by the Heart and Stroke Foundation
of Ontario (GIA#6614). M. Clyde is supported by an Ontario
Graduate Scholarship. The FLEX trial was registered on
Clinical Trials.gov (identiﬁer# NCT01623505).
No ﬁnancial disclosures were reported by the authors of
this paper.References
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